An improved DNA-based identification of fetuses at risk for HPA-1a (PlA1) neonatal alloimmune thrombocytopenia.
A simple and reliable procedure, based on DNA amplification and HpaII mapping, is proposed for the identification of fetuses at risk for HPA-1a (PlA1) neonatal alloimmune thrombocytopenia which could cause life-threatening haemorrhage, even in early fetal life. This typing procedure for HPA-1 alleles should help in deciding, very early, the therapeutic management of the fetuses at risk.